Tuesday, May 28, 2024

HomeStock MarketExelixis sues Cipla over Cabometyx generics (NASDAQ:EXEL)

Exelixis sues Cipla over Cabometyx generics (NASDAQ:EXEL)

Close-up of dictionary definition of the word patent

miteman

Exelixis (NASDAQ:EXEL) announced late Friday that it filed a lawsuit against Cipla, alleging that the Indian drugmaker has violated its patents related to the company’s lead asset, Cabometyx.

The lawsuit filed in a Delaware district court on Thursday follows Cipla’s


Source link

Bookmark (0)
ClosePlease login
RELATED ARTICLES
- Advertisment -spot_img

Most Popular

Sponsored Business

- Advertisment -spot_img